<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888719</url>
  </required_header>
  <id_info>
    <org_study_id>CWP-SKD-201</org_study_id>
    <nct_id>NCT00888719</nct_id>
  </id_info>
  <brief_title>Therapeutic Exploratory Study of CWP-0403</brief_title>
  <official_title>A Prospective, Randomized, Double Blinded, Multicenter and Therapeutic Exploratory Study to Comparatively Assess Efficacy and Safety of CWP-0403 in Type 2 Diabetes Patients Who Are Insufficiently Controlled by Diet and Exercise.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of the trial is to assess dose-dependency, efficacy and safety and to estimate
      optimum dosage for confirmatory study of CWP-0403 50mg, 100mg given twice daily for 12 weeks
      to type 2 diabetes patients who are insufficiently controlled by diet and exercise in
      comparison to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c before and after treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c target achievement rate(Ratio of the patients with HbA1c lower than 6.5% or 7%)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose level change and rate of change</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin, serum C-peptide level change</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-R and HOMA-β change rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride, LDL-cholesterol and HDL-cholesterol change</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CWP-0403 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CWP-0403 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CWP-0403 100mg</intervention_name>
    <description>100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks</description>
    <arm_group_label>CWP-0403 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.
Twice a day, 1 tablet at a time for 12 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CWP-0403 50mg</intervention_name>
    <description>50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks</description>
    <arm_group_label>CWP-0403 50mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of≥25 and &lt;75 with typeⅡ DM patients

          -  Patients whose level of HbA1c is over 7.0% and less than 10% within 4weeks of
             screening registration

          -  In spite of dietary and exercise treatment over 8weeks, the level of HbA1c is over
             6.5% and less than 10%.

          -  BMI between 20kg/㎡ and 40kg/㎡

          -  Out patients

          -  patients who agree the trial participation with written informed consent

        Exclusion Criteria:

          -  TypeⅠDM, Gestational diabetes.

          -  Patients who are being treated with insulin

          -  Fasting glucose level over 250mg/dL

          -  Patients who are not compliant with dietary and exercise treatment during 8 weeks of
             screening period. (Evaluated &quot;Bad&quot; and worse)

          -  Severe hepatic dysfunctions (i.e.: uncompensated hepatic cirrhosis)or AST or ALT level
             over 2.5times as high as UNL on screening visit.

          -  Severe renal dysfunctions (i.e.: renal failure) or serum creatinine level over
             1.5mg/dl

          -  Severe cardiac dysfunction(i.e.: heart failure ) or history of myocardial infarction
             within 6months of screening

          -  Chronic pulmonary disease or pulmonary infarction

          -  Pancreatitis patients

          -  Patients who are being treated for life threatening disease such as cancer, severe
             trauma or infection.

          -  Uncontrollable diabetic complications(neuropathy, retinopathy, nephrosis)

          -  Severe ketosis or experience of diabetic coma

          -  Intestinal disease affecting digestion or absorption or history of GI dissection
             surgery except for appendectomy.

          -  Pregnant, expecting to be pregnant or nursing female

          -  Excessive alcohol consumption (Over 80g of alcohol/day: Over 1 bottle of 360ml
             Soju/day)

          -  Participants of other clinical trials within 3 months of screening

          -  Patients medicated with following non-concomitant medications Insulins or oral
             antidiabetics Oral (for more than 1 week) or IV corticosteroids (External and inhaled
             corticosteroids excluded) appetite suppressant exenatide or other GLP-1 analogues
             Other medications in development

          -  Hypersensitive or intolerance to DPP4 inhibitory

          -  patients who are decided to be inappropriate for this trial subject by the
             investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KunHo Yoon</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon Medical School Gil Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hopital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Holly Family Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2009</study_first_posted>
  <last_update_submitted>November 3, 2010</last_update_submitted>
  <last_update_submitted_qc>November 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hyung kyu, Park</name_title>
    <organization>ChoongWae Pharma Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

